Cancer patients taking herbal medicines: a review of clinical purposes, associated factors, and perceptions of benefit or harm


It is advisable to refer to the publisher's version if you intend to cite from the work.

To link to this article DOI: http://dx.doi.org/10.1016/j.jep.2015.08.052

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement.

www.reading.ac.uk/centaur
CentAUR
Central Archive at the University of Reading
Reading's research outputs online
Cancer patients taking herbal medicines: A review of clinical purposes, associated factors, and perceptions of benefit or harm

Benjawan Poonthananiwatkul, Rachel L Howard, Elizabeth M Williamson, Rosemary H M Lim

PII: S0378-8741(15)30119-7
DOI: http://dx.doi.org/10.1016/j.jep.2015.08.052
Reference: JEP9717

To appear in: Journal of Ethnopharmacology

Received date: 1 June 2015
Revised date: 18 August 2015
Accepted date: 30 August 2015

Cite this article as: Benjawan Poonthananiwatkul, Rachel L Howard, Elizabeth M Williamson and Rosemary H M Lim, Cancer patients taking herbal medicines: A review of clinical purposes, associated factors, and perceptions of benefit or harm, Journal of Ethnopharmacology, http://dx.doi.org/10.1016/j.jep.2015.08.052

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Abstract

Ethnopharmacological relevance: Cancer patients in all cultures are high consumers of herbal medicines (HMs) usually as part of a regime consisting of several complementary and alternative medicine (CAM) modalities, but the type of patient, the reasons for choosing HM-CAM regimes, and the benefits they perceive from taking them are poorly understood. There are also concerns that local information may be ignored due to language issues. This study investigates aspects of HM-CAM use in cancer patients using two different abstracting sources: Medline, which contains only peer-reviewed studies from SCI journals, and in order to explore whether further data may be available regionally, the Thai national databases of HM and CAM were searched as an example.

Materials and Methods: the international and Thai language databases were searched separately to identify relevant studies, using key words chosen to include HM use in all traditions. Analysis of these was undertaken to identify socio-demographic and clinical factors, as well as sources of information, which may inform the decision to use HMs.

Results: Medline yielded 5,638 records, with 49 papers fitting the criteria for review. The Thai databases yielded 155, with none relevant for review. Factors associated with HM-CAM usage were: a younger age, higher education or economic status, multiple chemotherapy treatment, late stage of disease. The most common purposes for using HM-CAM cited by patients were to improve physical symptoms, support emotional health, stimulate the immune system, improve quality of life, and relieve side-effects of conventional treatment.

Conclusions: Several indicators were identified for cancer patients who are most likely to take HM-CAM. However, interpreting the clinical reasons why patients decide to use HM-CAM is hampered by a lack of standard terminology and thematic coding, because patients’ own descriptions are too variable and overlapping for meaningful comparison. Nevertheless, fears that the results of local studies published regionally are being missed, at least in the case of Thailand, appeared to be unfounded.

Cancer patients taking herbal medicines: a review of clinical purposes, associated factors, and perceptions of benefit or harm

Benjawan Poonthananiwatkul, Rachel L Howard, Elizabeth M Williamson*, Rosemary H M Lim. University of Reading School of Pharmacy, Whiteknights, Reading RG6 6AP

*Author for correspondence.
Abstract

Ethnopharmacological relevance: Cancer patients in all cultures are high consumers of herbal medicines (HMs) usually as part of a regime consisting of several complementary and alternative medicine (CAM) modalities, but the type of patient, the reasons for choosing such HM-CAM regimes, and the benefits they perceive from taking them are poorly understood. There are also concerns that local information may be ignored due to language issues. This study investigates aspects of HM-CAM use in cancer patients using two different abstracting sources: Medline, which contains only peer-reviewed studies from SCI journals, and in order to explore whether further data may be available regionally, the Thai national databases of HM and CAM were searched as an example.

Materials and Methods: the international and Thai language databases were searched separately to identify relevant studies, using key words chosen to include HM use in all traditions. Analysis of these was undertaken to identify socio-demographic and clinical factors, as well as sources of information, which may inform the decision to use HMs.

Results: Medline yielded 5,638 records, with 49 papers fitting the criteria for review. The Thai databases yielded 155, with none relevant for review. Factors associated with HM-CAM usage were: a younger age, higher education or economic status, multiple chemotherapy treatment, late stage of disease. The most common purposes for using HM-CAM cited by patients were to improve physical symptoms, support emotional health, stimulate the immune system, improve quality of life, and relieve side-effects of conventional treatment.

Conclusions: Several indicators were identified for cancer patients who are most likely to take HM-CAM. However, interpreting the clinical reasons why patients decide to use HM-CAM is hampered by a lack of standard terminology and thematic coding, because patients’ own descriptions are too variable and overlapping for meaningful comparison. Nevertheless, fears that the results of local studies published regionally are being missed, at least in the case of Thailand, appeared to be unfounded.

Keywords: cancer patient, complementary and alternative medicine, herbal medicine, food supplement, review.

Introduction

Cancer patients in all parts of the world are high users of herbal medicines (HMs), which they choose for clinical reasons related to their cancer diagnosis (Poonthananiwatkul 2015)
and which they usually take as part of a regime consisting of several complementary and alternative medicine (CAM) modalities (Alsanad et al 2014; McLay et al 2012). The contribution of HMs cannot easily be separated from those of other forms of CAM, although they are more likely to possess pharmacological effects and/or interact with conventional medicines. The specific reasons why patients take HM-CAM regimes have not been completely identified but include trying to actively treat cancer, reduce symptoms of the disease, ameliorate side effects associated with conventional treatments, prevent further recurrence or metastasis of the cancer, and to enhance general health in order to deal with the disease and its treatment (Poonthananiwatkul 2015; Alsanad et al 2014; Ernst 2009). A recent study of cancer patients at a traditional medicine hospice in Thailand suggested that in general herbal medicines were perceived to provide more benefit than harm, and a preliminary assessment of the herbal regime, using changes in symptom burden after staying at the hospice, supported this (Poonthananiwatkul 2015). HMs can be registered as medicines in the European Union, but not in most other countries, and ‘nutritional’ products are poorly regulated everywhere. HMs are often sold as ‘food’ or ‘dietary’ supplements to circumvent the regulations; however, as they are taken for therapeutic purposes they are considered to be HMs for the purposes of this study. The first step to addressing the problem of uncontrolled use of HMs as self-medication is therefore to explore the reasons why patients feel the need to take them. Perceptions of the efficacy and safety of these medicines influence the products chosen, although patients are unlikely to consider the indirect consequences of taking these medicines, including their interaction with conventional medicines or other supplements (Goey et al 2014; Zeller et al 2013). The issues posed by combining herbal medicines with conventional drugs have been well documented over the last decade (e.g. Alsanad et al 2014; McLay et al 2012; Williamson et al 2013) and patients in many countries are now being advised to avoid taking herbal medicines during conventional cancer treatment, although no published evidence is available to confirm this as a policy. The objective of this review is to summarize the socio-demographic and other factors that influence HM-CAM use in cancer patients, and their perceptions towards their benefit or harm.

Materials and methods

Search strategy
Data collected in ethnobotanical research has well-documented weaknesses, as critically reviewed by Heinrich et al (2009), and one of these is that datasets compiled regionally in local languages may not be available internationally. In order to investigate whether any
such ‘hidden studies’ were available, two separate reviews were carried out: the first, a search of Science Citation Indexed, peer-reviewed journals in Medline; the second, a search of the national databases in Thailand. The purpose of the Thai review was to act as an example to investigate whether extra information could be gained by casting the net more widely, despite the unreliability of non-peer-reviewed sources. The Thai databases were used as a test case because Thailand is a very high user of herbal medicines, they are comprehensive and we had access to the full dataset. The searches were restricted to 2003 onwards to provide a contemporary context and also because as a preliminary search found very few relevant studies prior to this. Even peer-review cannot guarantee quality so as many details as possible about each study (method, sample size, other findings) are included in table 1 to add context.

Information sources and searches
The global database Medline and the Thai on-line databases [Thailand Library Integrated System (ThaiLIS), Library of National Research Council of Thailand, Health Systems Research Institute Library, Thai Theses Online, Institute of Thai Traditional Medicine, Journal of Thai Traditional and Alternative medicine] (Thai Government 2014) were searched to identify literature on the experiences, attitudes or perceptions of cancer patients who had taken herbal medicines, using the following terms or their Thai language versions:

1) Complementary
2) Alternative
3) Medicine
4) Herbs
5) 1 or 2 or 3 or 4
6) Cancer
7) Attitude
8) 5 and 6 and 7
9) Limited to English
10) Limited to 2003 and 2014

The off-line Khampramong research database was also searched using the same terms, as an example of an institutional data resources. All English language studies published between 2003 and 2014 identifying the experiences/attitudes/perceptions/intended purposes of cancer patients regarding HIM were included. Review articles, operational (e.g. clinical guidelines) and health services (e.g. cancer screening) research, case reports,
studies on CAM which did not include HM use or surveys of other parties (such as physicians and other healthcare providers), and laboratory and animal studies were excluded. Studies looking purely at prevalence, trends and costs of herbal medicines were also omitted, as were studies on herb-drug combinations or side effects.

Data extraction

Full papers were obtained for studies considered relevant (figs 1 and 2) and read through by BP. To ensure validity, they were checked by Dr Saud Alsanad (College of Medicine, Al-Imam Mohammad Bin Saud Islamic University, Riyadh, KSA). The following data were extracted from the selected papers: author, year of publication, country, method used, response rate (%), sample size or calculation reported, cancer type, factors related to use of herbal medicine, purposes and thematic concepts cited for use. Factors such as age, gender, education level, income, type of cancer, previous conventional treatment and HM use were recorded, and also sources of information, which may influence decisions to use these products. Perceptions of benefit or harm resulting from taking these products were evaluated, but it must be emphasised that these are the opinions of patients who voluntarily took part in the studies cited, and are reported without any corroboration by independent assessment, clinical examination or biochemical tests. This is an intrinsic but unavoidable weakness of such studies.

5,638 records were found in the Medline database, but only 170 were judged relevant based on the title, i.e. they specifically examined herbal medicine use in cancer patients. 49 papers were eventually included in the review, as shown in figure 1. The Thai database search initially found 155 records, and 14 studies of herbal medicine use in cancer patients were selected based on the title (Fig 2). Titles and abstracts were read through by author BP and validated by a Thai speaker, Dr Supaporn Bunsiriluck (Sirindhorn College of Public Health, Thailand). No Thai language studies were found which fulfilled the criteria for inclusion, so no further analysis was undertaken for these studies.

5,638 records were found in the Medline database, but only 170 were judged relevant based on the title, i.e. they specifically examined herbal medicine use in cancer patients. 49 papers were eventually included in the review, as shown in figure 1. The Thai database search initially found 155 records, and 14 studies of herbal medicine use in cancer patients were selected based on the title (Fig 2). Titles and abstracts were read through by author BP and validated by a Thai speaker, Dr Supaporn Bunsiriluck (Sirindhorn College of Public Health, Thailand). No Thai language studies were found which fulfilled the criteria for inclusion, so no further analysis was undertaken for these studies.

Figure 1: Flow chart of the study selection process from the Medline database

Citations identified from databases (n= 5,638)

Studies not relevant based on the title of the study (n= 5,638)

These were review articles, operational research not involving herbal medicines, those concerning treatments not relevant to cancer patients, those with more than 25 patients, those not related to herbal medicine use, those not related to cancer, those without abstracts, those not written in English, those with abstracts not written in English.
Results

Potentially relevant articles regarding herbal medicine use by cancer patients from databases (n=170)

Studies not relevant and excluded based on title
(Excluded papers focussed on the prevalence of herbal medicines.)

Records eligible for full text screening, i.e. those regarding overall issues involved in using herbal medicines/attitudes/perceptions by cancer patients (n= 60)

Studies judged not relevant and excluded based on the review of abstract
(Excluded papers focussed on the specific results of using herb specific herbal regimes or reported side effects)

Included studies on experiences/attitude/perceptions of cancer patients after using herbs (n=49)

Studies not relevant and excluded based on the title of the study
(Excluded studies were case reports, health service studies, laboratory studies, animal studies, those involving

Potentially relevant articles of CAM and herbal medicine use in cancer patients (n=14)

Studies not relevant based on the review of abstract
(Excluded papers focussed mainly on the patterns/trends and use of herbal medicine)

No records eligible for full text screening concerning herbal medicine or CAM (experiences/attitudes/perceptions of cancer patients) (n= 0)

Figure 2: Flow chart of the study selection process from the Thai national databases
Purposes cited by cancer patients for taking herbal medicines as part of a CAM regime

The main reasons given by cancer patients as to why they use HM-CAM are illustrated in fig 3; which in fact shows that this type of analysis is not particularly useful, as there is so much overlap in potential meaning in the reasons cited by the patients themselves. We used the terms cited in the studies to try to avoid misinterpretation, but these are highly subjective. Not all studies used the same parameters, terminologies and methodologies, and more than one purpose was frequently cited by patients who also often used multiple types of CAM. Although all the studies reviewed included HM as a category of CAM, most could not differentiate findings from each modality, so it is not possible to ascribe all the findings to HM use. A further complication is that the line between HM and dietary supplements is not clear, and can depend on non-clinical issues such as legal classification.

CAM and HM in particular are to alleviate physical symptoms associated with cancer, but this category could easily include ‘improving general health and the ability to fight the disease’, as well as ‘treating cancer’ and ‘improving quality of life’, although these reasons were also described specifically. Similarly, ‘supporting emotional or mental health’ could include ‘taking an active role in treatment’, ‘managing stress’ and ‘feeling in control’. ‘Stimulating or boosting the immune system’ was also considered very important, and whereas few studies reported that using HM was intended to achieve a longer life-span, this is implicit in most other categories such as preventing recurrence and treating or curing cancer. Only one study one suggested that ‘dissatisfaction with conventional medicine’, but the fact that so many cancer patients use HM-CAM suggests that they do not think that conventional medicine has all the answers. Fig 3 therefore also illustrates the importance of using standardised terminology or the use of thematic coding, rather than relying on patients’ own descriptions verbatim for this kind of study. Despite this, almost all of the categories relate to the desire to be actively involved in treatment, and the impetus to use HM-CAM comes from patients, rather than practitioners.

Figure 3 Illustration of purposes cited by cancer patients for using herbal medicines as part of a CAM regime
Enhancing mainstream therapies
Achieving a longer life-span
Relieving cancer related symptoms
Curing cancer
Protecting against recurrent symptoms
Dissatisfaction with the conventional approach
Seeking a new treatment to heal illness
Relieving side effects from conventional...
Improving general quality of life
Stimulating the immune system
Supporting emotional health
Improving physical health

% of studies reporting each purpose
Table 1: Summary of research investigating related factors, reasons and study results of why cancer patients use herbal medicines

<table>
<thead>
<tr>
<th>No</th>
<th>Author (year published)</th>
<th>Country</th>
<th>Method*</th>
<th>Sample size</th>
<th>Cancer type</th>
<th>Clinical purpose for herbal medicine use and/or thematic analysis findings</th>
<th>Factors associated with herbal medicine use where identified</th>
<th>Other study findings, if stated</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Henderson &amp; Donatelle (2003)</td>
<td>USA</td>
<td>TQ</td>
<td>551</td>
<td>Breast</td>
<td>Improve physical and mental health, control symptoms, boost immune system.</td>
<td>Younger age, higher education, private health insurance to cover CAM.</td>
<td>66% used spiritual therapies/meditation in addition to HM; did not discuss with GPs.</td>
</tr>
<tr>
<td>3</td>
<td>Van der Weg &amp; Streuli (2003)</td>
<td>Switzerland</td>
<td>RAQ</td>
<td>108</td>
<td>Mixed</td>
<td>Assist conventional treatment, especially by using mistletoe therapy; ‘maintaining hope’, taking an active role in self-care.</td>
<td>Females, breast cancer, longer time since diagnosis.</td>
<td>79% discussed with doctor; 57% encouraged patients (none discouraged them). Mistletoe therapy most common by far.</td>
</tr>
<tr>
<td>4</td>
<td>Cui Y et al. (2004)</td>
<td>China</td>
<td>SAQ</td>
<td>1065</td>
<td>Breast</td>
<td>Treat cancer (81.5%), enhance immune system, prevent metastasis and reduce menopausal symptoms.</td>
<td>Younger, married, higher education or income, CT or RT, recurrence or metastasis.</td>
<td>Traditional Chinese medicine (TCM) most important modality (86.4%)</td>
</tr>
<tr>
<td>5</td>
<td>Salminen et al. 2004</td>
<td>Finland and Australia</td>
<td>SAQ</td>
<td>354</td>
<td>Breast</td>
<td>HMs part of an improvement in diet and lifestyle which were thought to cause cancer</td>
<td>Younger age, higher education, time from diagnosis.</td>
<td>Dietary changes: reduced sugar, animal fat, red meat; increased fruit and vegetable intake.</td>
</tr>
<tr>
<td>6</td>
<td>Astin et al. (2005)</td>
<td>Turkey</td>
<td>FGI</td>
<td>67</td>
<td>Breast</td>
<td>Manage symptoms, improve quality of life and enhance immune system.</td>
<td>Younger, more educated, more likely to use HM</td>
<td>A wide variety of other CAM used, mostly vitamins, minerals.</td>
</tr>
<tr>
<td>7</td>
<td>Hann et al. (2005)</td>
<td>USA</td>
<td>SAQ</td>
<td>608</td>
<td>Breast</td>
<td>Reduce recurrence, manage stress and play an active role in treatment.</td>
<td>Married, higher education.</td>
<td>Patients were cancer survivors, &gt;5 years post treatment.</td>
</tr>
<tr>
<td>8</td>
<td>Gupta et al. (2005)</td>
<td>USA</td>
<td>SAQ</td>
<td>242</td>
<td>Mixed</td>
<td>Not assessed.</td>
<td>Colorectal and breast cancer, later stages of cancer; previous experience of CT</td>
<td>25% took HMs that may interact with CT; 52.6% did not tell a healthcare professional.</td>
</tr>
<tr>
<td>9</td>
<td>Molassiotis et al. (2005)</td>
<td>14 EU countries</td>
<td>SAQ</td>
<td>956</td>
<td>Mixed</td>
<td>Improve physical ability to fight disease and improve psychological health.</td>
<td>Dramatic increase in CAM use after cancer diagnosis.</td>
<td>~49% used HM with ‘high levels of satisfaction; 3.2% reported no change; 4.4% adverse effects.</td>
</tr>
<tr>
<td>10</td>
<td>Trevena and Reeder (2005)</td>
<td>New Zealand</td>
<td>TQ</td>
<td>68</td>
<td>Not cancer patients</td>
<td>Not assessed.</td>
<td>Not assessed; study was in a random sample of 438 adults.</td>
<td>68% said ‘beneficial with conventional treatment’; 28% said ‘equal or better for cancer’</td>
</tr>
<tr>
<td>11</td>
<td>Helyer et al. (2006)</td>
<td>Canada</td>
<td>SAQ</td>
<td>36</td>
<td>Breast</td>
<td>‘Cure’ cancer, help the body to heal, boost the immune system and feel in control of treatment. Anxiety and depression found to be reduced</td>
<td>Many factors: e.g. married, younger, Asian ethnicity, higher socioeconomic class.</td>
<td>60% had taken ‘supplements’, 88% along with conventional drugs; 12% said HM and DS could replace them.</td>
</tr>
<tr>
<td>No</td>
<td>Author and Year (Published)</td>
<td>Country</td>
<td>Method*</td>
<td>Response Rate (%)</td>
<td>Sample Size</td>
<td>Cancer Type</td>
<td>Clinical Purpose for Herbal Medicine Use and/or Thematic Analysis Findings</td>
<td>Factors Associated with Herbal Medicine Use Where Identified</td>
</tr>
<tr>
<td>----</td>
<td>---------------------------</td>
<td>---------</td>
<td>---------</td>
<td>------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>12</td>
<td>Humpel and Jones (2006)</td>
<td>Australia</td>
<td>IDI</td>
<td>-</td>
<td>19</td>
<td>Mixed</td>
<td>Boost immune system, prevent cancer recurrence, and improve physical and emotional health.</td>
<td>Cancer diagnosis or end of conventional treatment prompted CAM use.</td>
</tr>
<tr>
<td>13</td>
<td>Lengacher et al. (2006)</td>
<td>USA</td>
<td>RAQ</td>
<td>105</td>
<td>Breast</td>
<td>To reduce symptoms; especially 'psychological' distress.</td>
<td>Higher level of education; dissatisfaction with medical treatment; CT</td>
<td>DS also used frequently.</td>
</tr>
<tr>
<td>14</td>
<td>Molassiotis et al. (2006)</td>
<td>8 EU countries</td>
<td>SAQ</td>
<td>-</td>
<td>111</td>
<td>Lung</td>
<td>HM mainly used to improve physical ability to fight cancer.</td>
<td>Younger, higher education, previous combination treatments for their cancer.</td>
</tr>
<tr>
<td>15</td>
<td>Williams et al. (2006)</td>
<td>USA</td>
<td>SAQ</td>
<td>-</td>
<td>37</td>
<td>Mixed</td>
<td>Pain or nausea of CT.</td>
<td>DS cited more commonly than HM.</td>
</tr>
<tr>
<td>17</td>
<td>Chen et al. (2008)</td>
<td>China</td>
<td>RAQ</td>
<td>-</td>
<td>5046</td>
<td>Breast</td>
<td>To alleviate menopausal symptoms and side effects of CT and tamoxifen</td>
<td>Chinese HM linked to younger age and severe menopausal symptoms</td>
</tr>
<tr>
<td>18</td>
<td>Gulluoglu et al. (2008)</td>
<td>Turkey</td>
<td>SAQ</td>
<td>-</td>
<td>129</td>
<td>Breast</td>
<td>To support their general health status.</td>
<td>Previous use; younger age, being married, RT.</td>
</tr>
<tr>
<td>19</td>
<td>Kremser et al. (2008)</td>
<td>Australia</td>
<td>SAQ</td>
<td>-</td>
<td>367</td>
<td>Breast</td>
<td>Improving wellbeing, boosting immune system, assist in treating cancer, educate recurrence.</td>
<td>HM associated with younger age; increase in all CAM in advanced stages of disease.</td>
</tr>
<tr>
<td>20</td>
<td>Lu et al. (2010)</td>
<td>Taiwan</td>
<td>IDI</td>
<td>-</td>
<td>7</td>
<td>Mixed</td>
<td>‘Cure’ disease; boost immunity, improve overall health, prolong life, and peace of mind.</td>
<td>Themes found: coping with psychological and physical distress, lifestyle disruption.</td>
</tr>
<tr>
<td>21</td>
<td>Piamjariyakul et al. (2010)</td>
<td>Thailand</td>
<td>RAQ</td>
<td>-</td>
<td>202</td>
<td>Mixed</td>
<td>CAM used: diet/life-style; mind and body control; HM ‘for hair loss’</td>
<td>Not assessed.</td>
</tr>
<tr>
<td>22</td>
<td>Oh et al. (2010)</td>
<td>Australia</td>
<td>SAQ</td>
<td>28.8</td>
<td>1,323</td>
<td>Mixed</td>
<td>Not assessed.</td>
<td>Most (83%) would be happier to accept CAM if offered by the hospital.</td>
</tr>
<tr>
<td>23</td>
<td>Teng et al. (2010)</td>
<td>China</td>
<td>SSI</td>
<td>-</td>
<td>121</td>
<td>Mixed</td>
<td>‘Cure’ cancer, boost immune system, increase quality of life, relieve cancer symptoms, and others.</td>
<td>Expenses for CAM paid for 40% of total medical cost, Western medicine only 20%.</td>
</tr>
<tr>
<td>24</td>
<td>Wanchai et al. (2010)</td>
<td>USA</td>
<td>SSI</td>
<td>-</td>
<td>9</td>
<td>Breast</td>
<td>Cope with disease and treatment, emotional support.</td>
<td>Kinship, social, educational, economical, and beliefs.</td>
</tr>
<tr>
<td>No</td>
<td>Author (year published)</td>
<td>Country</td>
<td>Method*</td>
<td>Response Rate (%)</td>
<td>Sample size</td>
<td>Cancer type</td>
<td>Clinical purpose for herbal medicine use and/or thematic analysis findings</td>
<td>Factors associated with herbal medicine use where identified</td>
</tr>
<tr>
<td>----</td>
<td>-------------------------</td>
<td>---------</td>
<td>---------</td>
<td>-------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>25</td>
<td>Wong et al. (2010a)</td>
<td>Singapore</td>
<td>RAQ</td>
<td>-</td>
<td>65</td>
<td>Mixed</td>
<td>Longer life, better quality of life, improved immunity.</td>
<td>Being male, advanced disease.</td>
</tr>
<tr>
<td>26</td>
<td>Wong et al. (2010b)</td>
<td>China</td>
<td>RAQ</td>
<td>97.5</td>
<td>82</td>
<td>Breast</td>
<td>Improve quality of life in several areas.</td>
<td>This was a clinical study on a particular combination.</td>
</tr>
<tr>
<td>27</td>
<td>Ali-Shtayeh et al. (2011)</td>
<td>Palestine</td>
<td>RAQ</td>
<td>-</td>
<td>1260</td>
<td>Mixed</td>
<td>Not assessed.</td>
<td>Most &gt;40 yrs, female, in rural areas.</td>
</tr>
<tr>
<td>28</td>
<td>Damery et al. (2011)</td>
<td>UK</td>
<td>SAQ</td>
<td>75.7</td>
<td>1498</td>
<td>Mixed</td>
<td>Not assessed.</td>
<td>Fewer than 20% &lt; 50 yrs old, most (~ 60%) HM users between 50 - 69 yrs.</td>
</tr>
<tr>
<td>29</td>
<td>Liu et al. (2011)</td>
<td>China</td>
<td>SSI</td>
<td>-</td>
<td>9</td>
<td>Mixed</td>
<td>Themes identified: HM benefits were medical, social and psychological</td>
<td>Not assessed.</td>
</tr>
<tr>
<td>31</td>
<td>Arthur et al. (2012)</td>
<td>USA</td>
<td>SSI</td>
<td>92</td>
<td>23</td>
<td>Mixed</td>
<td>To cope with disease; improve quality of life.</td>
<td>Optimism and a belief that one has the ability to act to achieve a good outcome.</td>
</tr>
<tr>
<td>32</td>
<td>Ben-Arye et al. (2012)</td>
<td>Israel</td>
<td>SAQ</td>
<td>-</td>
<td>275</td>
<td>Breast / Gyn.</td>
<td>Cope with CT effects and disease, provide emotional support.</td>
<td>Younger age, Jewish religion, but lesser degree of religiosity.</td>
</tr>
<tr>
<td>33</td>
<td>Heath et al. (2012)</td>
<td>Australia</td>
<td>RAQ</td>
<td>-</td>
<td>96</td>
<td>Mixed</td>
<td>Not assessed, but parents felt it had benefitted children and not caused further suffering.</td>
<td>No difference in parents who used CAM in age, income, education or faith.</td>
</tr>
<tr>
<td>34</td>
<td>McLay et al. (2012)</td>
<td>UK</td>
<td>SAQ</td>
<td>79.5%</td>
<td>453</td>
<td>Breast</td>
<td>Improving general health, boosting the immune system further cancer prophylaxis.</td>
<td>Use by friends and family, higher educational attainment.</td>
</tr>
<tr>
<td>35</td>
<td>McQuade et al. (2012)</td>
<td>China</td>
<td>SAQ</td>
<td>82.2</td>
<td>352</td>
<td>Mixed</td>
<td>Cure cancer, improve the immune system.</td>
<td>Cultural acceptance of TCM is high in China.</td>
</tr>
<tr>
<td>36</td>
<td>Nazik et al. (2012)</td>
<td>Turkey</td>
<td>SAQ</td>
<td>-</td>
<td>67</td>
<td>Gynaecologic</td>
<td>Boost the immune system.</td>
<td>No significant differences in demographics between users and non-users</td>
</tr>
<tr>
<td>37</td>
<td>Puataweepong et al. (2012)</td>
<td>Thailand</td>
<td>SAQ</td>
<td>-</td>
<td>248</td>
<td>Mixed</td>
<td>Alleviate symptoms, treat cancer, assist conventional treatment, improve physical and mental health</td>
<td>High income; cancer type.</td>
</tr>
<tr>
<td>No</td>
<td>Author (year published)</td>
<td>Country</td>
<td>Method*</td>
<td>Response Rate (%)</td>
<td>Sample size</td>
<td>Cancer type</td>
<td>Clinical purpose for herbal medicine use and/or thematic analysis findings</td>
<td>Factors associated with herbal medicine use where identified</td>
</tr>
<tr>
<td>----</td>
<td>-------------------------</td>
<td>---------</td>
<td>---------</td>
<td>-------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>40</td>
<td>Garland et al. (2013)</td>
<td>USA</td>
<td>RAQ</td>
<td>-</td>
<td>316</td>
<td>Mixed</td>
<td>Not assessed.</td>
<td>Female, higher education, breast cancer, length time after diagnosis.</td>
</tr>
<tr>
<td>41</td>
<td>O’Connor et al. (2013)</td>
<td>UK</td>
<td>SAQ</td>
<td>43</td>
<td>220</td>
<td>Mixed</td>
<td>To improve physical health.</td>
<td>Higher level of education</td>
</tr>
<tr>
<td>42</td>
<td>Tuna et al. (2013)</td>
<td>Turkey</td>
<td>RAQ</td>
<td>-</td>
<td>472</td>
<td>Mixed</td>
<td>Not assessed.</td>
<td>Influence of media (66%), friends and relatives (64%).</td>
</tr>
<tr>
<td>43</td>
<td>Bismark et al. (2014)</td>
<td>USA</td>
<td>SAQ</td>
<td>59</td>
<td>108</td>
<td>Lung</td>
<td>Improve general, emotional or spiritual health, boost immunity.</td>
<td>Being fearful regarding future.</td>
</tr>
<tr>
<td>44</td>
<td>Bonacchi et al. (2014)</td>
<td>Italy</td>
<td>SSI</td>
<td>82%</td>
<td>803</td>
<td>Mixed</td>
<td>Improve general health post-conventional treatment.</td>
<td>Female; having experienced and used CAM in past.</td>
</tr>
<tr>
<td>45</td>
<td>Dhanoa et al. (2014)</td>
<td>Malaysia</td>
<td>RAQ</td>
<td>-</td>
<td>274</td>
<td>Orthopaedic</td>
<td>Enhance physical well-being and improve wound-healing.</td>
<td>Influence of family and friends.</td>
</tr>
<tr>
<td>46</td>
<td>Huebner et al. (2014)</td>
<td>Germany</td>
<td>OQS</td>
<td>-</td>
<td>-</td>
<td>Mixed</td>
<td>To reduce unpleasant symptoms, support immune system and maintain health.</td>
<td>Breast cancer.</td>
</tr>
<tr>
<td>47</td>
<td>Ladas et al. (2014)</td>
<td>USA</td>
<td>RAQ</td>
<td>-</td>
<td>100</td>
<td>Mixed</td>
<td>About a third reported using HM and CAM for ‘curative’ purposes.</td>
<td>Not assessed.</td>
</tr>
<tr>
<td>48</td>
<td>Saghatchian et al. (2014)</td>
<td>France</td>
<td>SAQ</td>
<td>-</td>
<td>184</td>
<td>Breast</td>
<td>Improve cancer-related symptoms and support general health.</td>
<td>Higher education level and younger age.</td>
</tr>
<tr>
<td>49</td>
<td>Wilkinson and Stevens (2014)</td>
<td>Australia</td>
<td>SAQ</td>
<td>89</td>
<td>320</td>
<td>Mixed</td>
<td>Not assessed.</td>
<td>Not assessed.</td>
</tr>
</tbody>
</table>

Key to abbreviations: *RAQ= Researcher-administered questionnaire; SAQ = Self- administered questionnaire; TQ = telephone questionnaire; OQS= on-line questionnaire survey; IDI = in-depth interview; SSI = Semi-structured interview; FGI= Focus group interview.

Key to treatments and CAM modalities: HM = herbal medicine(s); HOM = homoeopathy; RT = radiotherapy; CT = chemotherapy; DS = dietary supplements (may sometimes include HM); TCM traditional Chinese medicine.
Factors associated with herbal medicines use as part of a CAM regime

In general, the results supported other studies investigating the frequency of general CAM use which have found that a younger age, higher level of education and income, ethnicity and being female, were linked to HM-CAM use, as detailed in table 1. As far as cancer patients are concerned, this diagnosis appears to act as an impetus to using HM-CAM, with the intention of improving general health to ‘fight disease’ as well as cope with side effects of conventional drug treatment, in a way not usually associated with other disease states.

The more serious disease states were associated with CAM which included HM and dietary supplements (HM-CAM). Multiple chemotherapy treatment was related to higher HM-CAM usage and many patients started using CAM (of any type) only after being diagnosed with cancer. However, those who had used HM-CAM for other purposes were also more likely to be associated with its use in cancer. A greater use of HM-CAM was noted in cancer patients who were in a recurrent or metastatic stage (e.g. Cui et al., 2004) and the longer the time since the initial cancer diagnosis, the more likely patients were to use HMs (Salminen et al., 2004). These reasons may be related to other factors such as ‘fearfulness about the future’ and ‘anxiety about possible recurrence’, which were also linked with a greater tendency to use HM-CAM (Correa-Velez et al., 2003, Bismark et al., 2014).

Experiences reported by patients after taking herbal medicines

The recorded incidence of herbal use varies widely, i.e. between 10.8% and 90.2%, but all the studies reviewed showed that at least 55% of patients believed they had had benefited, whereas few patients (8% to 18%) reported negative effects (Damery et al., 2011, Nazik et al., 2012, Molassiotis et al., 2006, Chen et al., 2008, Tuna et al., 2013, Bonacchi et al., 2014).

Perceived beneficial experiences: Previous studies have reported positive effects after HM-CAM use but results varied greatly. Between 22% and 90% of patients said they had experienced benefits, the most common being relief of pain, dyspepsia and fever, and improved appetite and patterns of sleep (Oh et al., 2010, Molassiotis et al., 2005, Puataweepong et al., 2012, Hyodo et al., 2005, Teng et al., 2010, Ladas et al., 2014, Trevena and Reeder, 2005). Other perceived benefits were a greater ability to cope with the illness and its treatment or specific effects in relieving pain and adverse effects of conventional medicine including chemotherapy (i.e. nausea), as well as alleviating severe depression or anxiety and improving emotional health, as shown in table 1.
Perceived negative experiences reported by patients after taking HMs: Negative effects from HM-CAM reported by cancer patients ranged from 3% to 9.4% and included pain, dyspepsia, abdominal pain and fatigue (Oh et al., 2010, Molassiotis et al., 2005, Puataweepong et al., 2012, Hyodo et al., 2005, Trevena and Reeder, 2005). As with perceived benefit, it is not possible to ascribe all of these to the HM-CAM treatment and some may be due to progression of the disease.

Other findings of the review

Concurrent use with conventional therapies: most studies found that over 50% of patients who used HM-CAM did so along with conventional medicines (e.g. Nazik et al., 2012, Gupta et al., 2005, Helyer et al., 2006), many to treat specifically the adverse effects of conventional treatment (e.g. Gupta et al., 2005, McLay JS et al., 2012).

Informing medical practitioners of HM use: differences were noted between countries but the number of studies cited was insufficient to draw any conclusions. Most strikingly, two US and two UK studies reported that the majority of patients surveyed did not tell their doctor of their HM-CAM use, whereas in two Australian studies, the majority either informed or intended to inform their doctor. In Turkey, Italy, Israel and Germany (1 study each), most patients discussed their HM-CAM use with their GP, but in Thailand, most did not (1 study).

Discussion

Many studies have investigated the use of CAM generally in cancer patients, which is commonplace (e.g. Teng et al 2010), and in some cases this has included HM (including dietary supplements). HM is the main form of CAM which can interact with conventional drugs, so the implications of HM use are more serious (e.g. Alsanad et al 2014) and therefore formed the focus of this investigation. As most users of CAM use more than one modality, we have examined all studies which specified the HM as part of their regime. Although in traditional Chinese medicine (TCM) for example, combining conventional with herbal medicine in cancer treatment is endorsed by physicians and may be beneficial (e.g. Hu et al 2015; Cui et al 2004), patients usually used HM-CAM on their own initiative and without informing their doctor, and many considered it was not necessary to do so.

The most common reasons for taking HM-CAM found in this study were linked to the desire to improve physical and mental symptoms and quality of life, and to help deal with the disease and its unpleasant treatment. As CAM is not sanctioned officially by most medical
authorities, and not usually covered by public insurance schemes, it requires independent research into self-care health options, for example by using the internet and media. This may be a reflection of the findings that younger patients and those of a higher educational and financial status were associated with a higher use of HM-CAM.

This study also showed that most of the relevant information on HM-CAM is available in the mainstream, peer-reviewed literature. A comprehensive set of Thai databases compiled from local studies was used as an example for exploration; however, it provided no new information and did not even identify two Thai clinical studies published internationally (Piamjariyakul et al 2010; Puataweepong et al. 2012). This is understandable since authors prefer to publish in SCI journals, although the results cannot be extrapolated elsewhere until further studies have been done.

Conclusions

This review identified several indicators for cancer patients who are most likely to take HM-CAM, using information taken from Medline. Fears that the results of local studies published regionally are being missed, at least in the case of Thailand, appeared to be unfounded. In addition to patient characteristics as described above, the use of HM-CAM was also associated with the type and stage of cancer and the side-effects of conventional treatment experienced. However, interpreting the specific clinical purposes why patients decide to use HM-CAM, and what they expected of and experienced from the treatments, is hampered by a lack of standard terminology and thematic coding. Patients’ own descriptions are too variable and overlapping for meaningful comparison, but even so, most the categories relate to a desire to be actively involved in treatment, to improve general health and aid recovery. The impetus to use HM-CAM comes mainly from patients, rather than practitioners, except in China where integration of TCM and conventional medicine for cancer treatment is more common.

References


Cancer patients taking herbal medicines: a review of clinical purposes, associated factors, and perceptions of benefit or harm

Records eligible for full text screening, i.e. those regarding overall issues involved in using herbal medicines, and experiences, attitudes or perceptions by cancer patients (n=60)

Included studies on experiences/ attitude/ perceptions of cancer patients after using herbal medicines (n=49)